Latest Headlines

  1. Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation And European Medicines Agency Orphan Medicinal Product Designation (OMPD) For NB4168 For The Treatment Of Ataxia Telangiectasia (A-T) 7/13/2026

    Niagen Bioscience, Inc., the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T).

  2. Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval For Segmented Production 7/8/2026

    Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), announced that its application for segmented production of antibody-drug conjugates (ADCs) at its Hangzhou site successfully passed a comprehensive inspection from three provincial regulatory bodies in China.

  3. Evogene And Tel Aviv University's Blavatnik Center For Drug Discovery Announce Joint Initiative To Accelerate AI-Driven Small-Molecule Drug Discovery 7/8/2026

    Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational chemistry company focused on the generative design of small molecules for the pharmaceutical and agricultural industries, and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University, today announced a strategic joint initiative aimed at accelerating the growth, development, and success of innovation originating from Israel's academic research ecosystem and focused on small-molecule drug discovery.

  4. Saol Therapeutics Resubmits The New Drug Application For SL1009 (DCA) For The Treatment Of Pyruvate Dehydrogenase Complex Deficiency (PDCD), An Ultra-Rare Disease 7/7/2026

    Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SL1009, sodium dichloroacetate (DCA), for the treatment of pyruvate dehydrogenase complex deficiency (PDCD), a rare, life-threatening mitochondrial disease with no FDA-approved therapies.

  5. Altasciences And Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough 7/7/2026

    Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025.

  6. Certara Accelerates Drug Discovery And Development With NVIDIA BioNeMo Agent Toolkit 7/7/2026

    Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks.

  7. Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery With Broad Analysis And International AI Initiative 7/7/2026

    Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, has recently reported that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX Bio”), successfully completed a broad analysis of SLC transport proteins and initiated an international AI drug discovery initiative with Boltz, PBC (“Boltz”), to accelerate the discovery of novel small-molecule modulators of these targets.

  8. The University Of Colorado Anschutz, Along With UCHealth And Children's Hospital Colorado, Form Strategic Alliance With Bayer To Advance Drug Development And Clinical Trials 7/7/2026

    Bayer, a global life sciences company, has announced a new strategic alliance focused on clinical trials collaboration with the University of Colorado Anschutz, UCHealth and Children's Hospital Colorado, establishing Bayer's first alliance of its kind with an academic medical center.

  9. Helix Announces Multi-Year Agreement With AstraZeneca To Support Genomic Research For Drug Discovery And Development 7/7/2026

    Helix, the leading enterprise genomics company, today announced a multi-year relationship with AstraZeneca, a global biopharmaceutical company.

  10. Novartis Agrees To Acquire Myricx Bio, Advancing Next-Generation Antibody-Drug Conjugate Innovation With A Novel NMTi Payload, Expanding Options For Cancer Patients 7/6/2026

    Novartis today announced that it has entered into an agreement to acquire Myricx Bio (“Myricx”), a privately held UK-based biotechnology company developing a new class of antibody-drug conjugates (ADCs), using N-myristoyltransferase inhibitor (NMTi) payloads.